Health Professionals
The information in this section is for health providers, such as doctors, pharmacists, nurses, medical assistants, etc. and not present as medical advice to health professionals.
Safety Alerts & NPRA Recent Updates
Ondansetron: Information updates on risk of birth defects |
Alemtuzumab (Lemtrada®): Revised indication, additional contraindications and risk minimisation measures |
Tumour Necrosis Factor alpha (TNFα): Kaposi’s Sarcoma |
Esmya (ulipristal acetate 5 mg): Withdrawal of product registration |
Gilenya® (fingolimod): New contraindication in pregnant women and in women of childbearing potential who are not using effective contraception |
Reporting ADR/AEFI by Healthcare Professionals
Please report ALL suspected Adverse Drug Reactions (ADRs) (including those for traditional products) and Adverse Events Following Immunisation (AEFIs) to the National Centre for Adverse Drug Reactions Monitoring.
Do not hesitate to report if some details are not known.The identities of Reporter, Patient and Institution will remain confidential.
Quality Reporting
Please use this form to report for quality reporting of registered product (e.g. quality, efficacy, labelling, packaging) NOT related to ADRs.
Products Search
Search Pharmaceutical, Complimentary & Alternative Products that registered with National Pharmaceutical Regulatory Agency, NPRA. You may also search cosmetic products notified with NPRA
NEWSLETTER: MADRAC BULLETIN
REAKSI DRUG SAFETY NEWS
awareness of adverse drug reactions reported, and stimulate additional adverse drug reaction reporting.
Consumer Information

Online Public Engagement
